Cargando…

Should Canadian patients look forward to aducanumab for Alzheimer disease?

Detalles Bibliográficos
Autores principales:	Watt, Jennifer A., Marple, Roger, Hemmelgarn, Brenda, Straus, Sharon E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	CMA Joule Inc. 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443286/ https://www.ncbi.nlm.nih.gov/pubmed/34518345 http://dx.doi.org/10.1503/cmaj.211134

Ejemplares similares

Les patients canadiens devraient-ils fonder leurs espoirs sur l’aducanumab pour la maladie d’Alzheimer?
por: Watt, Jennifer A., et al.
Publicado: (2021)

Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
por: Lalli, Giovanna, et al.
Publicado: (2021)

Aducanumab for Alzheimer’s disease?
por: Walsh, Sebastian, et al.
Publicado: (2021)

Aducanumab for Alzheimer’s disease: The never‐ending story that nurses should know
por: Petch, Joel, et al.
Publicado: (2021)

Under-Represented Populations Left Out of Alzheimer’s Disease Treatment with Aducanumab: Commentary on Ethics
por: Padala, Sanjana P., et al.
Publicado: (2022)

Disease-modifying drugs for Alzheimer disease: implications for people in Canada
por: Watt, Jennifer A., et al.
Publicado: (2023)

Practical Considerations in the Administration of Aducanumab for the Neurologist
por: Coerver, Katherine, et al.
Publicado: (2022)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
por: Wojtunik-Kulesza, Karolina, et al.
Publicado: (2023)

Looking Back; Looking Forward!
por: Turner, Jerrold R.
Publicado: (2015)

MHC Genomics and Disease: Looking Back to Go Forward
por: Dawkins, Roger L., et al.
Publicado: (2019)

Alzheimer disease neuropathology in a patient previously treated with aducanumab
por: Plowey, Edward D., et al.
Publicado: (2022)

Choosing Wisely: The Canadian Society of Nephrology’s List of 5 Items Physicians and Patients Should Question
por: Chan, Emilie, et al.
Publicado: (2017)

Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
por: Vaz, Miguel, et al.
Publicado: (2022)

Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab
por: Chertkow, Howard, et al.
Publicado: (2021)

Public Health in Big Cities: Looking Back, Looking Forward
por: Fielding, Jonathan E.
Publicado: (2015)

Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review
por: Beshir, Semira Abdi, et al.
Publicado: (2022)

Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease
por: Herring, William L., et al.
Publicado: (2021)

Looking back to look forward: Surviving COVID-19 and the future of the NHS
por: Vacek, Adam, et al.
Publicado: (2023)

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

Neurology and Therapy: Looking Back on 2018 and Forward to 2019
por: Sabbagh, Marwan, et al.
Publicado: (2019)

Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer’s Disease
por: Abyadeh, Morteza, et al.
Publicado: (2021)

Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price
por: Sinha, Pranay, et al.
Publicado: (2022)

Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer’s Disease
por: Geerts, Hugo, et al.
Publicado: (2021)

Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
por: Yigit, Vahit, et al.
Publicado: (2023)

Aducanumab: What about the Patient?
por: Petersen, Ronald C.
Publicado: (2021)

Alzheimer's disease therapeutic research: the path forward
por: Aisen, Paul S
Publicado: (2009)

What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?
por: Wallin, Anders, et al.
Publicado: (2022)

Firearms, pesticides, and suicide: A look back for a way forward
por: Betz, Marian E., et al.
Publicado: (2020)

Overview of Self-Management Resources Used by Canadian Chronic Kidney Disease Clinics: A National Survey
por: Donald, Maoliosa, et al.
Publicado: (2018)

Aducanumab as a Novel Treatment for Alzheimer’s Disease: A Decade of Hope, Controversies, and the Future
por: Esang, Michael, et al.
Publicado: (2021)

Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
por: Lin, Lin, et al.
Publicado: (2022)

Is Aducanumab for LMICs? Promises and Challenges
por: Gunawardena, Illangage P. C., et al.
Publicado: (2021)

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations
por: Cummings, J., et al.
Publicado: (2021)

The genetics of acute lung injury: looking back and pointing the way forward
por: Bajwa, Ednan K
Publicado: (2009)

Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA review
por: Dickson, Samuel P., et al.
Publicado: (2023)

Looking Forward: The Role of Academic Researchers in Building Sustainable Wastewater Surveillance Programs
por: Hoar, Catherine, et al.
Publicado: (2022)

Commentary: Patient Perspectives on Artificial Intelligence; What have We Learned and How Should We Move Forward?
por: Camaradou, Jennifer Catherine Louise, et al.
Publicado: (2023)

Understanding environmental influences on nutrition and physical activity behaviors: where should we look and what should we count?
por: Ball, Kylie, et al.
Publicado: (2006)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mpvq2dhs418od7grocbjdbh5ff